Adverse Effects of Pertussis and Rubella Vaccines

Page 205

Weibel RE, Stokes J, Buynak EB, Hilleman MR. 1972. Influence of age on clinical response to HPV-77 duck rubella vaccine. Journal of the American Medical Association 222:805-807.

Weibel RE, Villarejos VM, Klein EB, Buynak EB, McLean AA, Hilleman MR. 1980. Clinical and laboratory studies of live attenuated RA 27/3 and HPV 77-DE rubella virus vaccines. Proceedings of the Society for Experimental Biology and Medicine 165:44-49.

Witney EW. 1940. Neuritis following rubella (letter). British Medical Journal 1:831.

Table of Contents

Front Matter R1-R14

1 Executive Summary 1-8

2 Histories of Pertussis and Rubella Vaccines 9-31

3 Methodologic Considerations in Evaluating the Evidence 32-64

4 Evidence Concerning Pertussis Vaccines and Central Nervous System Disorders, Including Infantile Spasms, Hypsarrhythmia, Aseptic Meningitis, and Encephalopathy 65-124

5 Evidence Concerning Pertussis Vaccinces and Deaths Classified as Sudden Infant Death Syndrome (SIDS) 125-143

6 Evidence Concerning Pertussis Vaccines and Other Illnesses and Conditions 144-186

7 Evidence Concerning Rubella Vaccines and Arthritis, Radiculoneuritis, and Thrombocytopenic Purpura 187-205

Afterword on Research Needs 206-207

Bibliography 208-282

Glossary of Terms 283-292

Appendix A: Strategies for Gathering Information: Adverse Effects of Pertussis and Rubella Vaccines 293-319

Appendix B: Pertussis and Rubella Vaccines: A Brief Chronology 320-332

Appendix C: Animal Models for the Study of Whooping Cough and the Testing of Vaccine Materials 333-336

Appendix D: Technical Details of Power Calculations and Meta-Analyses 337-346

Appendix E: Possible Involvement of Aluminum Salts in Erythema Multiforme, Encephalopathy, or Other Adverse Events After Pertussis Immunization 347-348

Appendix F: Committee and Staff Biographies 349-354

Index 355-367